Screening for Sterilizing Activity of Antibiotic Combinations in an Acid Model of Rapidly Growing Mycobacteria during the Stationary Phase of Growth

被引:10
作者
Cremades, R. [1 ]
Santos, A. [1 ]
Rodriguez, J. C. [1 ]
Garcia-Pachon, E. [2 ]
Ruiz, M. [1 ]
Escribano, I. [1 ]
Royo, G. [1 ]
机构
[1] Hosp Gen Univ, Microbiol Sect, ES-03203 Elche, Spain
[2] Hosp Gen Univ, Sect Res Med, ES-03203 Elche, Spain
关键词
Bactericidal activity; Rapidly growing mycobacteria; Stationary growing; Moxifloxacin; IN-VITRO; FLUOROQUINOLONE ACTION; BACTERICIDAL ACTIVITY; DRUG SUSCEPTIBILITY; TUBERCULOSIS; RESISTANCE; PERSISTENCE; PREVENTION; DIAGNOSIS; BACILLI;
D O I
10.1159/000194973
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In view of the problems of correlation between the data provided by classical microbiological studies and clinical response, we designed an in vitro method to screen for the sterilizing activity of various antibiotics, individually or in combinations, against clinical isolates of various rapidly growing mycobacteria in the stationary phase. Material and Methods: We screened a large number of antibiotic combinations (4-16 mu g/ml) for their sterilizing capacity in 26 Mycobacterium fortuitum clinical isolates, 7 Mycobacterium chelonae and 2 Mycobacterium abscessus clinical isolates (10(5) CFU). Results: The best results against M. fortuitum were obtained with moxifloxacin, both on its own (13/26 strains) and in combination. This drug is also very active against M. chelonae (3/7 strains), and in combination with clarithromycin and amikacin exhibits sterilizing activity against all the strains studied. Combinations of clarithromycin with moxifloxacin or linezolid at high doses (16 mu g/ml) exhibit activity against M. abscessus. Conclusions: The most relevant finding of our study is the good activity of moxifloxacin against these microorganisms in the stationary phase. This indicates the need to confirm these data in animal models or clinical trials in order to determine their true clinical importance. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:114 / 118
页数:5
相关论文
共 32 条
[21]   Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis [J].
Kubendiran, G. ;
Paramasivan, C. N. ;
Sulochana, S. ;
Mitchison, D. A. .
JOURNAL OF CHEMOTHERAPY, 2006, 18 (06) :617-623
[22]  
Lipsitch M, 1998, INT J TUBERC LUNG D, V2, P187
[23]   Evaluation of killing kinetics of anti-tuberculosis drugs on Mycobacterium tuberculosis using a bacteriophage-based assay [J].
Marcel, Nimi ;
Nahta, Ajay ;
Balganesh, Meenakshi .
CHEMOTHERAPY, 2008, 54 (05) :404-411
[24]  
NUERMBERGER EL, 2003, AM J RESP CRIT CARE, V24
[25]   Mycobacterium abscessus: an emerging rapid-growing potential pathogen [J].
Petrini, Bjorn .
APMIS, 2006, 114 (05) :319-328
[26]   Drug Susceptibility of the Mycobacterium Genus: In Vitro Tests and Clinical Implications [J].
Rodriguez, J. C. ;
Garcia-Pachon, E. ;
Ruiz, M. ;
Royo, G. .
CURRENT CLINICAL PHARMACOLOGY, 2006, 1 (03) :277-289
[27]   Mutant prevention concentration:: a new tool for choosing treatment in nontuberculous mycobacterial infections [J].
Rodríguez, JC ;
Cebrián, L ;
López, M ;
Ruiz, M ;
Royo, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (04) :352-356
[28]   Application of molecular biology techniques to the diagnosis of nontuberculous mycobacterial infections [J].
Ruíz, M ;
Rodríguez, JC ;
Escribano, I ;
García-Martínez, J ;
Rodríguez-Valera, F ;
Royo, G .
APMIS, 2001, 109 (12) :857-864
[29]   Mycobacteria:: Genetics of resistance and implications for treatment [J].
Sander, P ;
Böttger, EC .
CHEMOTHERAPY, 1999, 45 (02) :95-108
[30]  
SANTOS A, J INFECT CH IN PRESS